The Use of Mind-Altering Substances: MDMA, Psilocybin, and Marijuana for Treating PTSD and Other Mental Distress
This course explores the revived research into psychedelics like MDMA, psilocybin and cannabis for treating PTSD, anxiety, depression and more, including outcomes, therapeutic mechanisms and safe integration with psychotherapy.
Provider
Details
Enrollment
Upcoming Cohort
Start date: July 13, 2026
Course Overview
This six-hour course (recording from the 30th International Trauma Conference) explores the therapeutic potential of psychedelics and cannabis for treating PTSD, anxiety, depression and more.
Learn about revived research into MDMA, psilocybin, and marijuana after decades of prohibition. Discover how psychedelic-assisted psychotherapy facilitates trauma healing, with lasting benefits seen in MAPS-sponsored MDMA trials. Review outcomes from psilocybin studies for cancer patients facing end-of-life distress. Examine the promise and limitations of cannabis for mental health. Gain perspectives from pioneering researchers and clinicians conducting psychedelic therapy.
Through video modules and discussions, develop knowledge of how psychedelics reduce defensive reactions, allowing deeper processing of emotions and memories. Consider how these treatments integrate with contemporary psychotherapy. Earn up to 6 CE credits distinguishing between psychedelics, weighing risks and benefits, and preparing to advise clients about safe, effective psychedelic-assisted healing.
Who is this for?
Mental health, rehab, and healthcare professionals, including therapists and psychologists.
About the Provider
PESI is a leading continuing education provider for mental health professionals, offering accredited online courses on psychedelic-assisted therapies including MDMA, psilocybin, ketamine, and microdosing, covering clinical frameworks, ethics, harm reduction, and client communication for therapists, counselors, nurses, and psychiatrists. Their trainings help clinicians build competence in this rapidly emerging therapeutic field and earn CE credits required for licensure.
View Pesi profileCourse Details
- Price$460
- FormatHybrid
- Lifecycle statusActive
- Skillspsychedelic psychotherapyPTSD treatmenttraumaanxietydepressioncannabismarijuanaMDMApsilocybinmental healthresearchhealingrisksbenefitsintegration
- Categories
You will be redirected to the provider's website
Related Courses
View all coursesCertificate in Psychedelic-Assisted Therapies & Research | CIISCIIS LogoCIIS Logo
A 12-month certificate in psychedelic-assisted therapies and research offered by CIIS. The program includes hybrid or online study and covers clinical competencies, research, cultural context, and ethical practice.
FDA On MDMA-Assisted Psychotherapy
This page discusses the FDA's rejection of MDMA-assisted psychotherapy and summarizes the rationale given for further research. It also reviews MDMA's history, reported therapeutic uses, and MAPS' response to the decision.
Automated status check: No valid upcoming cohort date found on the source page (checked 2026-04-15).
MAPS International MDMA-assisted Therapy Training Program
A collaboration between MAPS and the Clinical Psychedelic Lab at Monash University, this training program prepares mental healthcare professionals to support MDMA-assisted psychotherapy for PTSD. It combines online learning with a week-long in-person residential intensive and is limited to 65 trainees.
Automated status check: No valid upcoming cohort date found on the source page (checked 2026-04-15).